| Literature DB >> 29121660 |
Jing Qiu1, Zhiwei Zhou1, Jie Wang1, Yiying Wang1, Chunxing Liu1,2, Xingxiang Liu3, Yunfang Xu3, Lugang Yu4, Hui Zhou4, Jie Lin5, Zhirong Guo1, Chen Dong1.
Abstract
Metabolic diseases such as type 2 diabetes mellitus (T2DM) and metabolic syndromes (MetS) have been recognized as the important risk factors for asymptomatic intracranial vertebrobasilar stenosis (IVBS). Although fatty liver index (FLI) is significantly related with these diseases, the association between FLI and IVBS remains unclear. In the present study, 2368 participants (30-75 years) were recruited from a Chinese prospective cohort study of PMMJS. Amongst them, 2281 individuals who did not have IVBS at baseline were enrolled in the 6-year following-up study. In cross-sectional analysis based on the baseline characteristics, the results showed that FLI was positively related with IVBS prevalence. Compared to the participants with FLI < 30, the adjusted OR (95% CI) of IVBS was 2.07 (1.18, 3.62) and 2.85 (1.39, 5.18) in the groups of 30 ≤ FLI < 60 and FLI ≥ 60, respectively. In longitudinal analysis, the results showed that the participants with FLI ≥ 60 had an increased risk of asymptomatic IVBS compared to those with FLI < 30 [adjusted HR (95%CI): 1.65 (1.05, 2.60)]. Moreover, exclusion of persons with hypertension, T2DM and MetS did not alter the associations between FLI and asymptomatic IVBS. Therefore, our results suggest that elevated FLI is an independent risk factor for asymptomatic IVBS in Chinese adults.Entities:
Mesh:
Year: 2017 PMID: 29121660 PMCID: PMC5679613 DOI: 10.1371/journal.pone.0187502
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flow diagram for the included participants.
Characteristics of participants with or without IVBS in cross-sectional analysis.
| Characteristics | No asymptomatic IVBS | asymptomatic IVBS | P Value |
|---|---|---|---|
| Age (years) | 50.89±9.82 | 57.20±6.66 | 0.000 |
| Men (%) | 1837(80.53%) | 83(95.40%) | 0.001 |
| Smoking (%) | 954(41.82%) | 42(48.28%) | 0.232 |
| BMI (kg/m2) | 23.65±2.97 | 25.71±2.63 | 0.000 |
| WC (cm) | 82.28±8.59 | 88.86±6.63 | 0.000 |
| SBP (mmHg) | 116.2±12.84 | 120.5±14.00 | 0.002 |
| DBP (mmHg) | 75.77±9.10 | 80.02±9.63 | 0.000 |
| ALT (U/L) | 25.86±17.30 | 29.02±19.93 | 0.092 |
| AST (U/L) | 22.89±7.53 | 24.46±9.19 | 0.068 |
| GGT (U/L) | 33.54±34.04 | 36.47±23.74 | 0.199 |
| FLI | 28.88±23.34 | 44.63±24.55 | 0.000 |
| FPG (mmol/L) | 5.40±0.85 | 5.71±0.82 | 0.001 |
| TG (mmol/L) | 1.63±1.42 | 2.05±1.69 | 0.026 |
| TC (mmol/L) | 4.72±0.83 | 4.83±0.75 | 0.246 |
| LDL-c (mmol/L) | 2.89±0.73 | 2.95±0.70 | 0.432 |
| HDL-c (mmol/L) | 1.30±0.31 | 1.19±0.30 | 0.002 |
| Hypertension (%) | 214(9.38%) | 20(22.99%) | 0.000 |
| T2DM (%) | 57(2.50%) | 6(6.90%) | 0.012 |
| MetS (%) | 68(2.98%) | 8(9.20%) | 0.001 |
BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyltransferase; FLI: fatty liver index; FPG: fasting plasma glucose; TG: triglycerides; TC: total cholesterol; LDL-c: low density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; T2DM: type 2 diabetes mellitus; MetS: metabolic syndromes.
Associations of FLI with IVBS in cross-sectional analysis.
| FLI<30 | 30≤FLI<60 | FLI≥60 | ||
|---|---|---|---|---|
| IVBS cases | 28 | 32 | 27 | |
| Crude OR | 1.00(ref) | 2.80(1.67,4.69) | 4.49(2.61,7.72) | <0.0001 |
| Model 1 | 1.00(ref) | 2.06(1.21,3.53) | 2.92(1.64,5.21) | 0.0002 |
| Model 2 | 1.00(ref) | 2.07(1.18,3.62) | 2.68(1.39,5.18) | 0.0026 |
Model 1: Adjusted for age, gender, BMI, smoking, SBP and DBP
Model 2: Model 1 and ALT, AST, HDL-c, LDL-c and FPG.
Sensitivity analysis on the association between FLI with IVBS in cross-sectional analysis.
| Cases (%) | Unadjusted | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|---|
| OR (95%CI) | OR (95%CI) | OR (95%CI) | |||||
| FLI < 30 | 23 (1.79%) | 1.00 (ref) | — | 1.00 (ref) | — | 1.00(ref) | — |
| FLI ≥30 | 26 (5.63%) | 3.28 (1.85,5.80) | 0.000 | 2.69 (1.46,5.96) | 0.002 | 2.44 (1.26,4.74) | 0.008 |
Model 1: Adjusted for age, gender, BMI, smoking, SBP and DBP
Model 2: Model 1 and ALT, AST, HDL-c, LDL-c and FPG.
Baseline characteristics of participants with or without asymptomatic IVBS in longitudinal analysis.
| Characteristics | No asymptomatic IVBS | asymptomatic IVBS | |
|---|---|---|---|
| Age (years) | 50.53±9.92 | 55.14±7.30 | 0.000 |
| Men (%) | 1667(79.23%) | 170(96.05%) | 0.000 |
| Smoking (%) | 877(41.68%) | 77(43.50%) | 0.637 |
| BMI (kg/m2) | 23.52±2.81 | 25.18±4.16 | 0.000 |
| WC (cm) | 81.92±8.63 | 86.49±6.89 | 0.000 |
| SBP (mmHg) | 115.8±12.73 | 120.6±13.37 | 0.000 |
| DBP (mmHg) | 75.42±8.94 | 79.86±9.89 | 0.000 |
| ALT (U/L) | 25.58±17.26 | 28.94±17.45 | 0.004 |
| AST (U/L) | 22.79±7.58 | 23.95±6.98 | 0.022 |
| GGT (U/L) | 32.83±32.59 | 41.22±46.36 | 0.006 |
| FLI | 27.94±22.98 | 40.04±24.70 | 0.000 |
| FPG (mmol/L) | 5.39±0.85 | 5.58±0.82 | 0.004 |
| TG (mmol/L) | 1.60±1.41 | 1.96±1.55 | 0.001 |
| TC (mmol/L) | 4.71±0.82 | 4.87±0.89 | 0.013 |
| LDL-c (mmol/L) | 2.88±0.73 | 2.99±0.73 | 0.050 |
| HDL-c (mmol/L) | 1.30±0.31 | 1.22±0.27 | 0.000 |
| Hypertension (%) | 457(17.52%) | 73(30.17%) | 0.000 |
| T2DM (%) | 129(4.94%) | 14(5.79%) | 0.567 |
| MetS (%) | 152(5.83%) | 32(13.22) | 0.000 |
BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyltransferase; FLI: fatty liver index; FPG: fasting plasma glucose; TG: triglycerides; TC: total cholesterol; LDL-c: low density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; T2DM: type 2 diabetes mellitus; MetS: metabolic syndromes.
Fig 2The cumulative incident asymptomatic IVBS in three groups.
The results of Kaplan–Meier analysis showed that there was a significantly higher incidence of asymptomatic IVBS in participants with higher FLI compared to those with FLI < 30 (P < 0.001 for both FLI < 30 vs 30 ≤ FLI < 60 and vs FLI ≥ 60, respectively).
Associations of FLI with IVBS in cross-sectional analysis.
| FLI<30 | 30≤FLI<60 | FLI≥60 | ||
|---|---|---|---|---|
| IVBS cases | 74 | 60 | 43 | |
| Crude HR | 1.00 (ref) | 2.04 (1.45, 2.87) | 2.80 (1.92, 4.07) | 0.000 |
| Model 1 | 1.00 (ref) | 1.39 (0.98, 1.98) | 1.71 (1.15, 2.54) | 0.006 |
| Model 2 | 1.00 (ref) | 1.38 (0.97, 1.97) | 1.65 (1.05, 2.60) | 0.025 |
Model 1: Adjusted for age, gender, BMI, smoking, SBP and DBP
Model 2: Model 1 and ALT, AST, HDL-c, LDL-c and FPG.
Stratified analysis on the association between FLI and asymptomatic IVBS according to ALT, AST and GGT in longitudinal study (FLI < 30 vs FLI ≥ 30).
| Unadjusted | Adjusted | |||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| ALT (U/L) | ||||
| <21 | 2.28 (1.34,3.89) | 0.002 | 1.21 (0.67,2.18) | 0.520 |
| ≥21 | 1.85 (1.23,2.78) | 0.003 | 1.52 (0.98,2.37) | 0.064 |
| AST (U/L) | ||||
| <21 | 2.74 (1.65,4.54) | 0.000 | 1.49 (0.83,2.66) | 0.183 |
| ≥21 | 1.87 (1.28,2.75) | 0.001 | 1.32 (0.85,2.06) | 0.215 |
| GGT (U/L) | ||||
| <22 | 2.06 (1.07,3.97) | 0.031 | 0.99 (0.48,2.06) | 0.982 |
Adjusted for age, gender, BMI, smoking, SBP, DBP, HDL-c, LDL-c and FPG. When compared in different groups, HR (95% CI) was calculated by adjustment for other liver enzymes.
Sensitivity analysis on the association between FLI with IVBS in cross-sectional analysis.
| Cases (%) | Unadjusted | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|---|
| HR (95%CI) | HR (95%CI) | HR (95%CI) | |||||
| FLI < 30 | 63 (4.98%) | 1.00 (ref) | — | 1.00 (ref) | — | 1.00(ref) | — |
| FLI ≥30 | 49 (11.24%) | 2.33 (1.60,3.38) | 0.000 | 1.61 (1.09,2.37) | 0.017 | 1.44 (1.02,2.04) | 0.038 |
Model 1: Adjusted for age, gender, BMI, smoking, SBP and DBP
Model 2: Model 1 and ALT, AST, HDL-c, LDL-c and FPG.